Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer

NCT05553522 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

1

Enrollment

OTHER

Sponsor class

Stopped Slow enrollment

Conditions

Brain Metastases
HER2-positive Breast Cancer

Interventions

COMBINATION_PRODUCT: Combined use of SRS with Tucatinib, Trastuzumab, and Capecitabine

Sponsor

Baptist Health South Florida

Collaborators

[object Object]